Pfizer (PFE) Asset Writedowns and Impairment (2009 - 2026)

Pfizer has disclosed Asset Writedowns and Impairment across 18 years of filings, most recently posting $32.0 million for Q1 2026.

• In Q1 2026, Asset Writedowns and Impairment fell 85.71% year-over-year to $32.0 million; the TTM figure through Mar 2026 stood at -$192.0 million (down 132.0% YoY), while the FY2023 annual figure was $3.0 billion, up 445.45% from the prior year.
• Asset Writedowns and Impairment rose to $32.0 million in Q1 2026, from -$577.0 million in the prior quarter.
• Over the last five years, Asset Writedowns and Impairment for PFE reached as high as $2.5 billion in Q4 2023 and fell as low as -$577.0 million in Q4 2025.
• The 5-year median for Asset Writedowns and Impairment is $200.0 million (2022), against an average of $310.0 million.
• Annual changes were most pronounced in 2023 — Asset Writedowns and Impairment jumped 770.97% — and 2026, when it slumped 85.71%.
• A 5-year view of Asset Writedowns and Impairment shows it stood at $200.0 million in 2022, then jumped by 1150.5% to $2.5 billion in 2023, then tumbled by 90.4% to $240.0 million in 2024, then slumped by 340.42% to -$577.0 million in 2025, then surged by 105.55% to $32.0 million in 2026.
• According to Business Quant data, Asset Writedowns and Impairment over the past three periods registered $32.0 million, -$577.0 million, and $260.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.